Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

When you see that almost half of the companies in the Pharmaceuticals industry in Switzerland have price-to-sales ratios (or "P/S") below 4.7x, Cosmo Pharmaceuticals N.V. (VTX:COPN) looks to be giving off some sell signals with its 5.8x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.

Check out our latest analysis for Cosmo Pharmaceuticals

What Does Cosmo Pharmaceuticals' Recent Performance Look Like?

With revenue growth that's superior to most other companies of late, Cosmo Pharmaceuticals has been doing relatively well. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

Keen to find out how analysts think Cosmo Pharmaceuticals' future stacks up against the industry? In that case, our free report is a great place to start.

Do Revenue Forecasts Match The High P/S Ratio?

In order to justify its P/S ratio, Cosmo Pharmaceuticals would need to produce impressive growth in excess of the industry.

Taking a look back first, we see that the company grew revenue by an impressive 78% last year. The latest three year period has also seen an excellent 192% overall rise in revenue, aided by its short-term performance. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.

Looking ahead now, revenue is anticipated to climb by 19% per year during the coming three years according to the five analysts following the company. That's shaping up to be materially higher than the 3.6% each year growth forecast for the broader industry.

In light of this, it's understandable that Cosmo Pharmaceuticals' P/S sits above the majority of other companies. It seems most investors are expecting this strong future growth and are willing to pay more for the stock.

The Key Takeaway

It's argued the price-to-sales ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.

Our look into Cosmo Pharmaceuticals shows that its P/S ratio remains high on the merit of its strong future revenues. Right now shareholders are comfortable with the P/S as they are quite confident future revenues aren't under threat. Unless the analysts have really missed the mark, these strong revenue forecasts should keep the share price buoyant.

It's always necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Cosmo Pharmaceuticals, and understanding should be part of your investment process.

If these risks are making you reconsider your opinion on Cosmo Pharmaceuticals, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.